XML 28 R61.htm IDEA: XBRL DOCUMENT v2.4.0.6
Total Consideration Transferred (Detail) (Novozymes Biopharma Sweden Ab, USD $)
Dec. 20, 2011
Novozymes Biopharma Sweden Ab
 
Business Acquisition [Line Items]  
Cash consideration $ 26,445,000
Estimated fair value of contingent consideration 1,611,000
Total consideration transferred $ 28,056,000